

Standard chemotherapy with or without bevacizumab for
ovarian cancer (ICON7): overall survival results of a phase 3

Lancet Oncology, The

16, 928-936

DOI: [10.1016/s1470-2045\(15\)00086-8](https://doi.org/10.1016/s1470-2045(15)00086-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Discordance between the results and conclusions of ICON7. <i>Lancet Oncology</i> , The, 2015, 16, e478.	5.1	2
3	Discordance between the results and conclusions of ICON7 – Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e478-e479.	5.1	1
4	Management of cancer of the ovary. , 0, , 345-359.		0
5	BrÃves de lâ€™AERIO. <i>Oncologie</i> , 2015, 17, 595-598.	0.2	0
6	Bevacizumab in newly diagnosed ovarian cancer. <i>Lancet Oncology</i> , The, 2015, 16, 876-878.	5.1	8
7	Negative trials in ovarian cancer: is there such a thing as too much optimism?. <i>Ecancermedalscience</i> , 2016, 10, ed58.	0.6	7
8	The Cost-Effectiveness of Bevacizumab for the Treatment of Advanced Ovarian Cancer in Canada. <i>Current Oncology</i> , 2016, 23, 461-467.	0.9	7
9	Targeted therapy and immunotherapy in ovarian cancer. <i>Journal of the Korean Medical Association</i> , 2016, 59, 180.	0.1	1
10	Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. <i>Ecancermedalscience</i> , 2016, 10, 626.	0.6	33
11	Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 143-151.	1.8	22
12	The role of surgery in advanced epithelial ovarian cancer. <i>Ecancermedalscience</i> , 2016, 10, 666.	0.6	19
13	Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2113.	1.8	165
14	Cytotoxic and Pro-Apoptotic Effects of Cassane Diterpenoids from the Seeds of <i>Caesalpinia sappan</i> in Cancer Cells. <i>Molecules</i> , 2016, 21, 791.	1.7	30
15	Major clinical research advances in gynecologic cancer in 2015. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e53.	1.0	20
16	The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 231-238.	0.6	12
17	Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. <i>British Journal of Cancer</i> , 2016, 115, 228-235.	2.9	23
18	The role of cediranib in ovarian cancer: current status and further investigation. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 855-865.	0.5	0
19	SEOM Clinical Guideline in ovarian cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1206-1212.	1.2	15

#	ARTICLE	IF	CITATIONS
20	Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 1-12.	2.0	18
21	Reply to T.J. Kruser et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1282-1283.	0.8	1
22	LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer. <i>Scientific Reports</i> , 2016, 6, 38983.	1.6	71
23	Genitourinary tumours in the targeted therapies era. <i>Anti-Cancer Drugs</i> , 2016, 27, 917-943.	0.7	8
24	Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. <i>Gynecologic Oncology</i> , 2016, 142, 13-18.	0.6	2
25	Immune checkpoint inhibition in ovarian cancer. <i>International Immunology</i> , 2016, 28, 339-348.	1.8	122
26	Anti-angiogenic agents in ovarian cancer: past, present, and future. <i>Annals of Oncology</i> , 2016, 27, i33-i39.	0.6	115
27	The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial. <i>Value in Health</i> , 2016, 19, 431-439.	0.1	20
28	Same Data; Different Interpretations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3729-3732.	0.8	6
29	Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. <i>Clinical Oncology</i> , 2016, 28, 760-765.	0.6	7
30	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473.	0.8	318
31	Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Gynecologic Oncology</i> , 2016, 143, 3-15.	0.6	208
32	Management of relapsed ovarian cancer: a review. <i>SpringerPlus</i> , 2016, 5, 1197.	1.2	86
33	First-Line Chemotherapy for Ovarian Cancer: Inferences From Recent Studies. <i>Oncologist</i> , 2016, 21, 1286-1290.	1.9	2
34	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecologic Oncology</i> , 2016, 143, 27-34.	0.6	81
35	The rise of genomic profiling in ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1337-1351.	1.5	18
36	Ovarian cancer. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16061.	18.1	761
37	Antiangiogenic therapies in ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 139-143.	0.3	16

#	ARTICLE	IF	CITATIONS
38	Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets. <i>Oncology Letters</i> , 2016, 12, 3264-3272.	0.8	16
39	Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy. <i>ESMO Open</i> , 2016, 1, esmoopen-2016-000117.	2.0	5
40	Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma. <i>EJNMMI Research</i> , 2016, 6, 42.	1.1	5
41	Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab. <i>Medicine (United States)</i> , 2016, 95, e4232.	0.4	16
46	Prediction of anti-angiogenesis escape. <i>Gynecologic Oncology</i> , 2016, 141, 80-85.	0.6	15
47	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 78-89.	5.1	205
48	Nintedanib and ovarian cancer: standardise surgery in trials?. <i>Lancet Oncology</i> , The, 2016, 17, 9-11.	5.1	4
49	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. <i>Journal of Biomolecular Screening</i> , 2016, 21, 626-633.	2.6	29
50	Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. <i>Gynecologic Oncology</i> , 2016, 141, 49-56.	0.6	33
51	Ovarian cancer: is chemotherapy before surgery the way forward?. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 5-12.	0.4	1
52	Current and emerging treatment options in the management of advanced ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1063-1076.	0.9	8
53	Targeted agents and combinations in ovarian cancer: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 441-454.	1.1	12
54	Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. <i>International Journal of Clinical Oncology</i> , 2016, 21, 456-461.	1.0	29
55	Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. <i>Drug Resistance Updates</i> , 2016, 24, 55-69.	6.5	52
56	Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 335-348.	2.0	22
57	Sequential tests for non-proportional hazards data. <i>Lifetime Data Analysis</i> , 2017, 23, 339-352.	0.4	8
58	An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Practice, 2017, 23, 454-469.	0.5	9
60	Internationally Comparable Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. <i>Clinical Oncology</i> , 2017, 29, 151-152.	0.6	0

#	ARTICLE	IF	CITATIONS
61	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2017, 75, 245-258.	1.3	82
62	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. <i>Annals of Oncology</i> , 2017, 28, 711-717.	0.6	125
63	The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 687-696.	1.0	9
64	Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1118-1122.	1.2	7
65	Ovarian cancer stem cells more questions than answers. <i>Seminars in Cancer Biology</i> , 2017, 44, 67-71.	4.3	128
66	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. <i>European Journal of Cancer</i> , 2017, 70, 111-121.	1.3	70
67	Updates and current challenges in microRNA research for personalized medicine in ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 927-943.	1.4	18
68	MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. <i>Cancer Science</i> , 2017, 108, 886-896.	1.7	32
69	Precision Medicine in Gynecology and Obstetrics. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , ,	0.0	1
70	Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. <i>British Journal of Cancer</i> , 2017, 116, 1294-1301.	2.9	13
72	Targeted Therapies for Ovarian Cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 139-152.	1.4	95
73	The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1850-1855.	1.2	5
74	Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress. <i>Current Oncology Reports</i> , 2017, 19, 83.	1.8	49
75	Clinical and genetic predictors of paclitaxel neurotoxicity based on patient-versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. <i>Annals of Oncology</i> , 2017, 28, 2733-2740.	0.6	52
76	IGF system targeted therapy: Therapeutic opportunities for ovarian cancer. <i>Cancer Treatment Reviews</i> , 2017, 60, 90-99.	3.4	65
77	Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients. <i>Drugs and Aging</i> , 2017, 34, 821-831.	1.3	4
79	FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. <i>Gynecologic Oncology</i> , 2017, 147, 3-10.	0.6	36
80	Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature. <i>Oncology Letters</i> , 2017, 14, 3327-3336.	0.8	6

#	ARTICLE	IF	CITATIONS
81	The role of Cediranib in ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1637-1648.	0.9	31
82	Therapeutic Implications of Angiogenesis in Cancer. , 2017, , 171-216.		0
83	Nintedanib in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1073-1081.	1.9	19
84	Malignant Brenner tumor of the ovary: Review and case report. <i>Gynecologic Oncology Reports</i> , 2017, 22, 26-31.	0.3	34
85	Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis. <i>Gynecologic Oncology</i> , 2017, 146, 504-513.	0.6	39
86	Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 50-58.	1.2	61
88	Optimism and the continued promise of maintenance chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 879-880.	1.1	2
89	Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 71-83.	0.5	11
90	Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel+carboplatin combination therapy in patients with epithelial ovarian cancer?. <i>Anti-Cancer Drugs</i> , 2017, 28, 922-927.	0.7	5
91	BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study. <i>BMC Cancer</i> , 2017, 17, 89.	1.1	8
92	Ovarian Cancers. , 2017, , .		1
93	Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. <i>Oncogene</i> , 2017, 36, 912-921.	2.6	53
94	The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 59-73.	1.6	22
95	Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 126-138.	1.4	32
96	Antiangiogenic Therapy Should be Considered Standard Treatment in the Adjuvant Therapy of Epithelial Ovarian Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 3-7.	0.1	0
97	Front-line therapy of advanced ovarian cancer: new approaches. <i>Annals of Oncology</i> , 2017, 28, viii46-viii50.	0.6	41
98	Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. <i>BMJ: British Medical Journal</i> , 2017, 359, j4530.	2.4	423
99	Neoadjuvant, adjuvant and long-term intravenous/intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy for ovarian cancer. <i>Journal of Peritoneum (and Other Serosal Surfaces)</i> , 2017, , .	0.1	1

#	ARTICLE	IF	CITATIONS
100	Ovarian Cancer Incidence Corrected for Oophorectomy. <i>Diagnostics</i> , 2017, 7, 19.	1.3	10
101	The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 210.	1.8	20
102	Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 507.	1.8	32
103	Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1458.	1.8	14
104	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients. <i>Disease Markers</i> , 2017, 2017, 1-9.	0.6	44
106	Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 13.	3.6	26
107	Ovarian Cancer: Bevacizumab as Adjuvant Treatmentâ€™Not Yet. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 9-10.	0.1	0
108	Bevacizumab in ovarian cancer: A critical review of phase III studies. <i>Oncotarget</i> , 2017, 8, 12389-12405.	0.8	100
109	Cancer Immunotherapy. , 2017, , 32-65.		1
110	Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1521-1525.	1.0	14
111	Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 10703-10713.	0.8	52
112	Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3471-3479.	2.0	12
113	ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e1030-e1039.	2.5	10
114	An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 448-452.	1.2	1
115	Antiangiogenic therapies in ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 18-26.	0.3	1
116	Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. <i>Endocrine-Related Cancer</i> , 2018, 25, R303-R318.	1.6	126
117	Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (â‰¥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 729-737.	1.2	22
118	Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions. <i>Clinical Therapeutics</i> , 2018, 40, 361-371.	1.1	41

#	ARTICLE	IF	CITATIONS
119	Resistance to Inhibitors of Angiogenesis. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 211-236.	0.1	2
120	Diffusion of Bevacizumab Across Oncology Practices. Medical Care, 2018, 56, 69-77.	1.1	9
121	The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review. Biomedicine and Pharmacotherapy, 2018, 102, 1127-1144.	2.5	42
122	Challenges of Oncoimmunology for Ovarian and Breast Cancers. , 2018, , 607-619.		0
123	Advances in ovarian cancer therapy. Cancer Chemotherapy and Pharmacology, 2018, 81, 17-38.	1.1	393
124	First-line treatment of ovarian cancer: questions and controversies to address. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876823.	1.4	32
125	The Chemoprevention of Ovarian Cancer: the Need and the Options. Current Pharmacology Reports, 2018, 4, 250-260.	1.5	12
127	Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. International Journal of Gynecological Cancer, 2018, 28, 903-914.	1.2	27
129	Emerging growth factor receptor antagonists for ovarian cancer treatment. Expert Opinion on Emerging Drugs, 2018, 23, 1-16.	1.0	2
130	Epithelial Ovarian Cancer. , 2018, , 253-289.e14.		3
131	Endocrine therapy in ovarian cancer: where do we stand?. Current Opinion in Obstetrics and Gynecology, 2018, 30, 17-22.	0.9	17
132	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clinical Cancer Research, 2018, 24, 777-783.	3.2	171
133	Moving From Mutation to Actionability. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 495-503.	1.8	4
134	A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer. Case Reports in Oncological Medicine, 2018, 2018, 1-6.	0.2	4
135	Increased expression of Na ⁺ /H ⁺ exchanger isoform 1 predicts tumor aggressiveness and unfavorable prognosis in epithelial ovarian cancer. Oncology Letters, 2018, 16, 6713-6720.	0.8	11
136	Biological Activity of Resveratrol on an Ovarian Cancer Cell. , 2018, , 231-244.		0
137	Current First-line Therapy for Ovarian Cancer: A Comprehensive Review. Obstetrical and Gynecological Survey, 2018, 73, 650-657.	0.2	9
138	Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint. British Journal of Cancer, 2018, 119, 1456-1463.	2.9	43

#	ARTICLE	IF	CITATIONS
139	Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 983-996.	0.9	94
140	Targeting Angiogenesis. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1041-1055.	0.9	11
141	Living Through Ovarian Cancer Treatment. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1073-1085.	0.9	4
142	Diagnosis and Treatment of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 943-964.	0.9	185
143	A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal. <i>Cell Reports</i> , 2018, 25, 3706-3720.e8.	2.9	20
144	Progress in <i>BRCA</i> -Mutated Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2567-2568.	13.9	18
145	Radiomics: a Novel CT-Based Method of Predicting Postoperative Recurrence in Ovarian Cancer. , 2018, 2018, 4130-4133.		8
146	The role of tumor microenvironment in resistance to anti-angiogenic therapy. <i>F1000Research</i> , 2018, 7, 326.	0.8	47
147	Profile and validation of dysregulated long non-coding RNAs and mRNAs in ovarian cancer. <i>Oncology Reports</i> , 2018, 40, 2964-2976.	1.2	8
148	Secondary cytoreduction in ovarian cancer: who really benefits?. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 873-879.	0.8	7
149	METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. <i>Gynecologic Oncology</i> , 2018, 151, 356-365.	0.6	139
150	A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study. <i>BMC Cancer</i> , 2018, 18, 904.	1.1	36
151	Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer. <i>International Journal of Hyperthermia</i> , 2018, 35, 370-374.	1.1	28
152	Low-grade Serous Ovarian Carcinoma. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 972-976.	0.8	27
153	CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer. <i>Epigenomics</i> , 2018, 10, 1397-1413.	1.0	14
154	A comparison of matched interim analysis publications and final analysis publications in oncology clinical trials. <i>Annals of Oncology</i> , 2018, 29, 2384-2390.	0.6	11
155	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 200, 1207-1214.	0.2	26
156	Surgical and Medical Management of Epithelial Ovarian Cancer. , 2018, , 884-904.		0

#	ARTICLE	IF	CITATIONS
157	Novel Systemic Treatments in High Grade Ovarian Cancer. , 0, , .		0
158	Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer â€œESMO-MCBS scores. <i>Cancer Treatment Reviews</i> , 2018, 69, 233-242.	3.4	9
159	<i>Gynecologic Cancer.</i> , 2018, , 121-178.		0
162	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. <i>Clinical Oncology</i> , 2018, 30, 515-524.	0.6	16
163	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). <i>Targeted Oncology</i> , 2018, 13, 469-479.	1.7	38
164	The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 521-528.	1.0	24
165	Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments. <i>Molecules</i> , 2018, 23, 444.	1.7	11
166	An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023. <i>BMC Cancer</i> , 2018, 18, 771.	1.1	17
167	Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. <i>European Journal of Pharmacology</i> , 2018, 837, 64-71.	1.7	3
168	Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1519-1531.	2.0	21
169	First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis. <i>PLoS ONE</i> , 2018, 13, e0195134.	1.1	7
170	The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2018, 38, 3619-3625.	0.5	9
171	Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach. <i>Journal of Translational Medicine</i> , 2018, 16, 73.	1.8	19
173	The role of cancer stem cells and the therapeutic potential of TRX-E-002-1 in ovarian cancer. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 465-475.	0.5	2
174	Loading Lovastatin into Camptothecinâ€œFloxuridine Conjugate Nanocapsules for Enhancing Anti-metastatic Efficacy of Cocktail Chemotherapy on Triple-negative Breast Cancer. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 29385-29397.	4.0	21
175	Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 243-257.	0.8	52
176	Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. <i>Current Opinion in Pharmacology</i> , 2018, 41, 114-121.	1.7	97
177	Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. <i>British Journal of Cancer</i> , 2018, 119, 12-18.	2.9	9

#	ARTICLE	IF	CITATIONS
178	Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 943-946.	0.6	2
179	Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target. <i>Cancers</i> , 2019, 11, 1147.	1.7	54
180	Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2398-2405.	0.8	28
181	Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2386-2397.	0.8	16
182	Overcoming Resistance to PARP Inhibition. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 161-189.	0.1	0
184	Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. <i>Journal of Cancer</i> , 2019, 10, 3717-3727.	1.2	46
185	Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProFiLER programme. <i>European Journal of Cancer</i> , 2019, 118, 156-165.	1.3	11
186	Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1050-1056.	1.2	39
187	Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review. <i>Journal of Ovarian Research</i> , 2019, 12, 103.	1.3	68
188	Bevacizumab prescribing practices for epithelial ovarian cancer in Australia. <i>Internal Medicine Journal</i> , 2019, 49, 1334-1335.	0.5	0
189	Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study. <i>Radiation Oncology</i> , 2019, 14, 179.	1.2	11
190	TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR) Tj ETQq1 1 0.784314 rgBT /Ov	1.2	108
191	No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2707-2708.	0.8	2
192	Olaparib maintenance for first-line treatment of ovarian cancer: Will SOLO1 reset the standard of care?. <i>Future Oncology</i> , 2019, 15, 1845-1853.	1.1	12
193	Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model. <i>PLoS ONE</i> , 2019, 14, e0222828.	1.1	0
194	A New Therapeutic Strategy for Recurrent Ovarian Cancer – Bevacizumab beyond Progressive Disease. <i>Healthcare (Switzerland)</i> , 2019, 7, 109.	1.0	8
195	Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Old and Novel Questions. <i>Journal of Clinical Oncology</i> , 2019, 37, 3168-3169.	0.8	3
197	Synthetic lethality guiding selection of drug combinations in ovarian cancer. <i>PLoS ONE</i> , 2019, 14, e0210859.	1.1	16

#	ARTICLE	IF	CITATIONS
198	Ovarian Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 67-88.	0.7	12
199	Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 137-154.	0.7	3
201	<p>Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4119-4128.	0.9	2
202	Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2317-2328.	0.8	289
203	Ovarian cancer and the evolution of subtype classifications using transcriptional profiling&€€. <i>Biology of Reproduction</i> , 2019, 101, 645-658.	1.2	33
204	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203
205	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 612.	1.0	5
206	Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e152-e166.	1.8	12
207	Low grade serous ovarian carcinoma: identifying variations in practice patterns. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 174-180.	1.2	9
208	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	5.1	68
209	Peptide-mediated delivery of therapeutic mRNA in ovarian cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 141, 180-190.	2.0	62
210	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 280-304.	157.7	821
211	Microarray profiling and co-expression network analysis of lncRNAs and mRNAs in ovarian cancer. <i>Cell Death Discovery</i> , 2019, 5, 93.	2.0	19
212	Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1380-1390.	0.8	178
213	Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1359-1364.	0.8	7
214	ESMO&€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019, 30, 672-705.	0.6	665
215	ESMO&€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 728-760.	1.2	167
216	A Computed Tomography-Based Radiomic Prognostic Marker of Advanced High-Grade Serous Ovarian Cancer Recurrence: A Multicenter Study. <i>Frontiers in Oncology</i> , 2019, 9, 255.	1.3	44

#	ARTICLE	IF	CITATIONS
217	OVA66 promotes tumour angiogenesis and progression through enhancing autocrine VEGF-VEGFR2 signalling. <i>EBioMedicine</i> , 2019, 41, 156-166.	2.7	24
218	High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. <i>International Journal of Molecular Sciences</i> , 2019, 20, 952.	1.8	381
219	Epithelial ovarian cancer. <i>Lancet, The</i> , 2019, 393, 1240-1253.	6.3	1,039
220	Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. <i>Cancers</i> , 2019, 11, 416.	1.7	49
221	A successfully treated primary peritoneal carcinosarcoma and serous carcinoma of stage IIIC rescued from hypovolemic shock due to tumor rupture. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2019, 58, 296-297.	0.5	2
222	Cancer drug development: The missing links. <i>Experimental Biology and Medicine</i> , 2019, 244, 663-689.	1.1	72
223	Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. <i>Clinical Cancer Research</i> , 2019, 25, 5342-5350.	3.2	33
224	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. <i>Endocrine Connections</i> , 2019, 8, R10-R26.	0.8	33
225	Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 890.	1.8	34
226	TOP2A as marker of response to pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancers. <i>Journal of Ovarian Research</i> , 2019, 12, 17.	1.3	20
227	<p></p>First-line treatment of women with advanced ovarian cancer: focus on bevacizumab</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1095-1103.	1.0	53
228	Major clinical research advances in gynecologic cancer in 2018. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e18.	1.0	29
231	Phase III trials in ovarian cancer: The evolving landscape of front line therapy. <i>Gynecologic Oncology</i> , 2019, 153, 436-444.	0.6	17
232	Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of MÅ¼llerian origin. <i>Gynecologic Oncology</i> , 2019, 153, 223-229.	0.6	7
233	Proposals on Kaplanâ€™Meier plots in medical research and a survey of stakeholder views: KMunicate. <i>BMJ Open</i> , 2019, 9, e030215.	0.8	33
234	Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review. <i>Asian Journal of Oncology</i> , 2019, 05, 01-18.	0.2	0
235	Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S308-S308.	0.7	0
236	Palliative urinary diversion in patients with malignant ureteric obstruction due to gynaecological cancer. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, e855-e861.	0.8	6

#	ARTICLE	IF	CITATIONS
239	New strategies in ovarian cancer treatment. <i>Cancer</i> , 2019, 125, 4623-4629.	2.0	92
240	Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4794.	1.2	23
241	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	13.9	1,176
242	Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. <i>Obstetrics and Gynecology</i> , 2019, 134, 1253-1259.	1.2	19
243	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	0.6	3
244	Maintenance Therapy in Metastatic Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 615-623.	0.6	4
245	Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy. <i>Cancer</i> , 2019, 125, 4582-4586.	2.0	23
246	Molecular Assessment of Ovarian Cancer and Translation to Clinical Management. , 2019, , 501-519.		0
247	New Treatment Options for Ovarian Cancer. , 2019, , 533-540.		0
248	Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KOGG 3041). <i>Gynecologic Oncology</i> , 2019, 152, 61-67.	0.6	26
249	Development of a multiplexed giant magnetoresistive biosensor array prototype to quantify ovarian cancer biomarkers. <i>Biosensors and Bioelectronics</i> , 2019, 126, 301-307.	5.3	61
250	Molecular-targeted therapies and precision medicine for endometrial cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 108-120.	0.6	38
251	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 53-60.	0.6	40
253	Ovarian cancer in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27512.	0.8	17
254	Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review. <i>Gynecologic and Obstetric Investigation</i> , 2019, 84, 107-117.	0.7	22
255	Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 137-145.	0.6	21
256	PARP inhibitors in ovarian cancer. <i>Cancer Treatment Reviews</i> , 2019, 73, 1-9.	3.4	158
257	Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. <i>Future Oncology</i> , 2019, 15, 543-561.	1.1	10

#	ARTICLE	IF	CITATIONS
258	When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 902-909.	0.3	26
259	Final results from GCI/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. <i>International Journal of Cancer</i> , 2020, 146, 439-448.	2.3	40
260	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. <i>Clinical Cancer Research</i> , 2020, 26, 1288-1296.	3.2	29
261	Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer. <i>JAMA Network Open</i> , 2020, 3, e1918939.	2.8	40
262	Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics. <i>Cancer</i> , 2020, 126, 1717-1726.	2.0	35
263	A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 689-694.	0.6	16
264	TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy. <i>Life Sciences</i> , 2020, 241, 117171.	2.0	7
265	Prognostic value of muscle measurement using the standardized phase of computed tomography in patients with advanced ovarian cancer. <i>Nutrition</i> , 2020, 72, 110642.	1.1	21
266	Maintenance Therapy in the Primary Treatment of Epithelial Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 80-85.	0.6	0
267	Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study. <i>Clinical Sarcoma Research</i> , 2020, 10, 18.	2.3	10
268	Newly diagnosed ovarian cancer: Which first-line treatment?. <i>Cancer Treatment Reviews</i> , 2020, 91, 102111.	3.4	23
269	Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy. <i>International Journal of Pharmaceutics</i> , 2020, 591, 119986.	2.6	30
270	<p>Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9857-9863.	1.0	10
271	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 134.	6.9	36
272	Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 445-453.	1.0	15
273	Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance. <i>Gynecologic Oncology</i> , 2020, 159, 604-606.	0.6	3
274	Are antiangiogenics a good "partner"™ for immunotherapy in ovarian cancer?. <i>Angiogenesis</i> , 2020, 23, 543-557.	3.7	10
275	Vascular endothelial growth factor- α as a promising therapeutic target for the management of psoriasis. <i>Experimental Dermatology</i> , 2020, 29, 687-698.	1.4	23

#	ARTICLE	IF	CITATIONS
276	Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?. <i>Cancers</i> , 2020, 12, 3296.	1.7	13
277	Treatment of epithelial ovarian cancer. <i>BMJ</i> , The, 2020, 371, m3773.	3.0	359
278	Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 758.	1.8	97
279	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 137.	7.1	79
280	Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience. <i>Frontiers in Oncology</i> , 2020, 10, 1095.	1.3	8
281	Clinical significance of p27 Kip1 expression in advanced ovarian cancer. <i>Applied Cancer Research</i> , 2020, 40, .	1.0	3
282	Validation of the Mexican-Spanish Version of the EORTC QLQ-OV28 Instrument for the Assessment of Quality of Life in Women with Ovarian Cancer. <i>Archives of Medical Research</i> , 2020, 51, 690-699.	1.5	2
283	Novel monoclonal antibody against integrin $\alpha 3$ shows therapeutic potential for ovarian cancer. <i>Cancer Science</i> , 2020, 111, 3478-3492.	1.7	5
284	First-line treatment of ovarian cancer FIGO stages IIIB-IV: focus on therapy with bevacizumab - our experience. <i>Libri Oncologici</i> , 2020, 47, 64-70.	0.1	1
285	The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study. <i>Journal of Cancer</i> , 2020, 11, 6178-6187.	1.2	12
286	Frontline Management of Epithelial Ovarian Cancer—Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research. <i>Journal of Clinical Medicine</i> , 2020, 9, 2830.	1.0	4
287	COVID-19 and Gynecological Cancers: A Summary of International Recommendations. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1750-1757.	0.3	2
288	Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives. <i>Cancers</i> , 2020, 12, 2414.	1.7	10
289	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1569-1575.	1.2	10
290	<p></p>The Role of CCL20-CCR6 Axis in Ovarian Cancer Metastasis</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12739-12750.	1.0	14
291	Current Trends in Cancer Immunotherapy. <i>Biomedicines</i> , 2020, 8, 621.	1.4	34
292	The Dawning of the Age of Personalized Medicine in Gynecologic Oncology. <i>Cancers</i> , 2020, 12, 3135.	1.7	2
293	Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. <i>Nature Communications</i> , 2020, 11, 5583.	5.8	99

#	ARTICLE	IF	CITATIONS
294	Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1689-1696.	0.5	12
295	Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial. <i>Translational Cancer Research</i> , 2020, 9, 2164-2167.	0.4	4
296	From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. <i>Cancers</i> , 2020, 12, 1330.	1.7	7
297	The prognostic value of ITGA and ITGB superfamily members in patients with high grade serous ovarian cancer. <i>Cancer Cell International</i> , 2020, 20, 257.	1.8	25
298	Current and future strategies for treatment of ovarian clear cell carcinoma. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 1678-1689.	0.6	9
299	Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 165-188.	1.0	10
300	First-Line Management of Advanced High-Grade Serous Ovarian Cancer. <i>Current Oncology Reports</i> , 2020, 22, 64.	1.8	30
301	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (ProTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	3.2	43
302	State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1579-1590.	0.9	10
303	Trends in bacterial resistance among perioperative infections in patients with primary ovarian cancer: A retrospective 20-year study at an affiliated hospital in South China. <i>Journal of International Medical Research</i> , 2020, 48, 030006052092878.	0.4	2
304	The recent progress and therapy in endometriosis-associated ovarian cancer. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 227-232.	0.6	23
305	CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4625-4632.	3.2	47
306	Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. <i>Future Oncology</i> , 2020, 16, 225-246.	1.1	63
307	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. <i>Diagnostics</i> , 2020, 10, 146.	1.3	56
308	Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa026.	1.4	21
309	Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer. <i>Pharmacogenomics</i> , 2020, 21, 721-727.	0.6	5
310	EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1762.	1.7	17
311	Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model. <i>Cancers</i> , 2020, 12, 1645.	1.7	25

#	ARTICLE	IF	CITATIONS
312	Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 379-385.	0.6	89
313	Development of a near infrared protein nanoprobe targeting Thomsen-Friedenreich antigen for intraoperative detection of submillimeter nodules in an ovarian peritoneal carcinomatosis mouse model. <i>Biomaterials</i> , 2020, 241, 119908.	5.7	7
314	Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 379-386.	0.6	23
315	<p>Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1561-1568.	1.0	38
316	A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 214-221.	0.6	2
317	Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment. <i>Cell Reports</i> , 2020, 30, 525-540.e7.	2.9	61
318	The influence of bevacizumab on the costs of ovarian cancer treatment in routine clinical practice. <i>Acta OncolÃ³gica</i> , 2020, 59, 453-457.	0.8	1
319	Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer. <i>Drug Discovery Today</i> , 2020, 25, 1232-1238.	3.2	28
320	Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?. <i>Current Treatment Options in Oncology</i> , 2020, 21, 49.	1.3	7
321	Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 509-514.	1.2	9
322	Comparing Paclitaxelâ€“Carboplatin with Paclitaxelâ€“Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIc Serous-Type Tubo-Ovarian Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2213.	1.2	33
323	Bevacizumab (AvastinÂ®) in cancer treatment: A review of 15Âyears of clinical experience and future outlook. <i>Cancer Treatment Reviews</i> , 2020, 86, 102017.	3.4	573
324	Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 213-220.	1.2	22
325	PARP Inhibitors in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1572-1575.	13.9	9
326	Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 6478.	1.6	8
327	Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1409-1420.	1.1	28
328	The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. <i>Annals of Surgical Oncology</i> , 2020, 27, 1780-1787.	0.7	13
329	Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study. <i>Anticancer Research</i> , 2020, 40, 1543-1550.	0.5	1

#	ARTICLE	IF	CITATIONS
330	The Multifactorial Role of PARP-1 in Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 739.	1.7	31
331	Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 886.	1.7	12
332	The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. <i>Cancer</i> , 2020, 126, 2553-2560.	2.0	11
333	Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?. <i>Clinical and Translational Oncology</i> , 2021, 23, 536-542.	1.2	5
334	Impact of nonspecific death on overall survival in early-stage epithelial ovarian cancer patients. <i>Current Problems in Cancer</i> , 2021, 45, 100621.	1.0	0
335	MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , 2021, 41, 223-223.	1.9	0
336	The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 285-311.	0.8	5
337	Objective responses to first-line neoadjuvant carboplatin+paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 277-288.	5.1	34
338	Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 302-311.	0.6	25
339	Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 110-113.	1.2	3
340	Clear cell carcinoma of the ovary: a clinical and molecular perspective. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 605-616.	1.2	79
341	Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 103-110.	1.9	9
342	Application of Second-Generation Sequencing in the Diagnosis and Treatment of Gynecological Tumors. <i>Advances in Clinical Medicine</i> , 2021, 11, 2689-2697.	0.0	0
343	Epithelial Ovarian Cancer and Cancer Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1330, 21-32.	0.8	4
344	Ovarian Cancer Stem Cells: Characterization and Role in Tumorigenesis. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1330, 151-169.	0.8	10
345	Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature. <i>Current Oncology</i> , 2021, 28, 661-670.	0.9	3
346	CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. <i>Clinical Epigenetics</i> , 2021, 13, 15.	1.8	10
347	Pressurized Intraperitoneal Aerosol Chemotherapy-Related Clinical Trials in the Treatment of Peritoneal Metastases. <i>Oncology</i> , 2021, 99, 601-610.	0.9	2

#	ARTICLE	IF	CITATIONS
348	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. <i>Seminars in Cancer Biology</i> , 2021, 77, 67-82.	4.3	12
349	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 191-226.	2.3	356
350	Use of Bevacizumab in Advanced Ovarian Cancer: Consensus from an Expert Panel Oncologists. <i>Indian Journal of Gynecologic Oncology</i> , 2021, 19, 1.	0.1	2
351	Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 4219.	1.6	37
352	Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103209.	2.0	11
353	The timing of venous thromboembolism in ovarian cancer patients: A nationwide Danish cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 992-1000.	1.9	13
354	Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. <i>Cancers</i> , 2021, 13, 1298.	1.7	24
355	Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 116.	3.5	23
356	An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. <i>Current Oncology</i> , 2021, 28, 1114-1124.	0.9	4
357	Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 543-554.	1.9	13
358	Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies. <i>Cancers</i> , 2021, 13, 1694.	1.7	1
359	Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study. <i>Gynecologic Oncology</i> , 2021, 161, 244-250.	0.6	6
360	Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery. <i>ESMO Open</i> , 2021, 6, 100098.	2.0	12
361	Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. <i>Cancers</i> , 2021, 13, 2067.	1.7	7
362	PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience. <i>JCO Global Oncology</i> , 2021, 7, 506-511.	0.8	10
364	Clinical Significance of Mesenteric Lymph Node Involvement in the Pattern of Liver Metastasis in Patients with Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 7606-7613.	0.7	5
365	Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1055-1063.	0.8	5
366	Characterization of the Early Years of Bevacizumab Use for First-Line Treatment of Ovarian Cancer in the United States. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00918.	1.4	2

#	ARTICLE	IF	CITATIONS
368	Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 875-882.	1.2	19
369	Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort. <i>BMC Cancer</i> , 2021, 21, 525.	1.1	3
370	The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2021, 161, 601-612.	0.6	16
371	Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). <i>Gynecologic Oncology</i> , 2021, 161, 382-388.	0.6	7
372	The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?. <i>ESMO Open</i> , 2021, 6, 100144.	2.0	77
373	The impact of body composition on treatment in ovarian cancer: a current insight. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1065-1074.	1.3	11
374	Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline. <i>JCO Global Oncology</i> , 2021, 7, 1032-1066.	0.8	21
375	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II-IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103324.	2.0	6
376	Frontline Maintenance Treatment for Ovarian Cancer. <i>Current Oncology Reports</i> , 2021, 23, 97.	1.8	3
377	Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing. <i>Cancers</i> , 2021, 13, 2901.	1.7	31
378	Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3177.	1.7	15
380	Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103336.	2.0	3
381	Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer. <i>Future Oncology</i> , 2021, 17, 2291-2304.	1.1	2
382	Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 5413-5422.	0.9	3
383	Treatment of advanced-stage ovarian cancer including combination of intra-abdominal chemotherapy. <i>Journal of Gynecological Cancer</i> , 2021, 20, 28-35.	0.0	0
384	Endometriosis-associated cancer: modern aspects of etiopathogenesis, treatment and rehabilitation. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 287-294.	0.2	1
385	Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1348-1355.	1.2	3
386	The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 78, 14-14.	1.4	0

#	ARTICLE	IF	CITATIONS
387	The Detection of Stem-Like Circulating Tumor Cells Could Increase the Clinical Applicability of Liquid Biopsy in Ovarian Cancer. <i>Life</i> , 2021, 11, 815.	1.1	2
388	Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 489-496.	0.7	7
389	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. <i>Acta Clinica Belgica</i> , 2021, , 1-13.	0.5	4
390	Dynamic prediction and analysis based on restricted mean survival time in survival analysis with nonproportional hazards. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 207, 106155.	2.6	8
391	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , 2021, 39, 2486-2496.	0.8	26
392	Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2021, 162, 482-495.	0.6	31
393	Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review. <i>Anticancer Research</i> , 2021, 41, 4673-4685.	0.5	8
394	AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 4529.	1.0	10
395	Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 78, 64-73.	1.4	9
396	Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer. <i>Medicine (United States)</i> , 2021, 100, e27130.	0.4	3
397	Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2021, 41, 4603-4607.	0.5	0
398	Risk of Thrombo-Embolitic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 4603.	1.7	10
399	The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. <i>Cancer Treatment Reviews</i> , 2021, 100, 102294.	3.4	21
400	Principles of radiation therapy and chemotherapy in gynecologic cancer. , 2022, , 618-636.e1.		2
401	Systemic Therapy for Gynecologic Malignancies. , 2021, , 155-159.		0
402	A high-performance microfluidic detection platform to conduct a novel multiple-biomarker panel for ovarian cancer screening. <i>RSC Advances</i> , 2021, 11, 8124-8133.	1.7	10
403	Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States. <i>JAMA Network Open</i> , 2020, 3, e2028620.	2.8	18
404	Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 534-546.	2.9	54

#	ARTICLE	IF	CITATIONS
405	Low-grade Serous Tumors: Are We Making Progress?. <i>Current Oncology Reports</i> , 2020, 22, 8.	1.8	13
406	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 418-425.	0.6	7
407	Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. <i>Obstetrics and Gynecology</i> , 2021, 137, 108-121.	1.2	150
408	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016, 126, 1885-1896.	3.9	101
409	Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan. <i>PLoS ONE</i> , 2017, 12, e0175703.	1.1	8
410	Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer. <i>Current Gynecologic Oncology</i> , 2017, 15, 5-23.	0.1	16
411	RETROSPECTIVE ANALYSIS OF LONG-TERM SURVIVAL OUTCOMES OF PRIMARY CYTOREDUCTION AND NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH OVARIAN CANCER STAGE III&IV. <i>Malignant Tumours</i> , 2018, 8, 86-94.	0.1	2
412	Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival. <i>Oncotarget</i> , 2015, 6, 36815-36824.	0.8	29
413	VE-cadherin cleavage by ovarian cancer microparticles induces β -catenin phosphorylation in endothelial cells. <i>Oncotarget</i> , 2016, 7, 5289-5305.	0.8	17
414	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 26181-26191.	0.8	15
415	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016, 7, 35132-35143.	0.8	9
416	Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in "Real-world" Patients. <i>Anticancer Research</i> , 2016, 36, 4947-4950.	0.5	5
417	Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer. <i>Anticancer Research</i> , 2017, 37, 3955-3960.	0.5	12
418	Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2018, 22, 1-264.	1.3	106
419	A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer. <i>Yonsei Medical Journal</i> , 2020, 61, 284.	0.9	6
420	Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3523.	1.2	1
421	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e17.	1.0	22
422	Targeted therapy of ovarian cancer including immune check point inhibitor. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 798-804.	0.7	40

#	ARTICLE	IF	CITATIONS
423	NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 896-909.	2.3	200
424	New Therapies for Ovarian Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 619-621.	2.3	19
425	Chemotherapy of ovarian cancer in elderly patients. Cancer Biology and Medicine, 2015, 12, 292-301.	1.4	10
426	The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers. , 2021, , 59-133.		0
427	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. Journal of Gynecologic Oncology, 2021, 32, e95.	1.0	5
430	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynecology and Obstetrics, 2021, 155, 61-85.	1.0	145
431	A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes. Biomedicines, 2021, 9, 1384.	1.4	4
432	Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer. Journal of the Chinese Medical Association, 2021, Publish Ahead of Print, .	0.6	12
433	Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients. Journal of Comparative Effectiveness Research, 2022, 11, 13-27.	0.6	1
434	PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188633.	3.3	20
435	Epithelial Ovarian Cancers: On-Target is Better than Near-Target. Chemotherapy, 2016, 05, .	0.0	0
436	First-Line Systemic Therapy (Chemo/Antiangiogenics). , 2017, , 95-112.		0
437	The Value of Anti-angiogenics in Ovarian Cancer Therapy. , 2017, , 1-15.		0
438	Signal Transduction and Targeted Therapy for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 23-67.	0.0	0
439	Strategies for the Management of Epithelial Ovarian Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 155-164.	0.0	0
441	Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial. Oncotarget, 2018, 9, 12599-12608.	0.8	1
443	What first-line therapy is optimal for patients with advanced ovarian cancer?. Current Gynecologic Oncology, 2018, 16, 89-95.	0.1	0
444	Modern aspects of antiangiogenic therapy in ovarian cancer. Meditsinskiy Sovet, 2018, , 17-21.	0.1	0

#	ARTICLE	IF	CITATIONS
445	Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations. <i>Drugs in Context</i> , 2018, 7, 1-9.	1.0	3
446	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
447	The Value of Anti-angiogenics in Ovarian Cancer Therapy. , 2019, , 529-543.		0
448	High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma. <i>Oncology Letters</i> , 2019, 18, 4900-4906.	0.8	2
449	Oligopeptides for Immunotherapy Approaches in Ovarian Cancer Treatment. <i>Current Drug Discovery Technologies</i> , 2019, 16, 285-289.	0.6	4
450	Primary ovarian cancer: possibilities for improving treatment outcomes. <i>Meditinskiy Sovet</i> , 2019, , 150-156.	0.1	1
451	Glucagonoma Masquerading as a Mucinous Cancer of the Ovary: Lessons from Cell Biology. , 0, , .		0
452	Supervivencia global y supervivencia libre de progresi3n en pacientes con c4ncer de ovario avanzado en la era del bevacizumab : experiencia en un centro oncol3gico de Medell4n-Colombia.. <i>Revista Colombiana De Hematolog4a Y Oncolog4a</i> , 2020, 7, 18-25.	0.0	0
453	The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2021, , .	2.9	3
455	The latest first-line treatment options for ovarian cancer: focus on maintenance therapy. <i>Meditinskiy Sovet</i> , 2020, , 62-68.	0.1	0
456	Immunology and Immunotherapy of Ovarian Cancer. , 2020, , 487-540.		0
457	The Role of Medical Therapy for Menigiomas. , 2020, , 201-215.		0
458	Upfront Maintenance Poly(Adenosine Diphosphate Ribose) Polymerase Inhibitors in Ovarian Cancer: A Ray of Hope or Just a Mirage!. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 173-181.	0.1	0
459	Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling. <i>Medical Decision Making</i> , 2021, , 0272989X2110262.	1.2	0
460	Primary ovarian cancer cell inhibition by human Wharton's Jelly stem cells (hWJSCs): Mapping probable mechanisms and targets using systems oncology. <i>Bioinformatics</i> , 2015, 11, 529-34.	0.2	2
461	Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine. <i>M4dica</i> , 2015, 10, 376-381.	0.4	1
462	Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy. <i>Current Oncology Reports</i> , 2021, 23, 148.	1.8	7
463	A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin. <i>Journal of Ovarian Research</i> , 2021, 14, 157.	1.3	1

#	ARTICLE	IF	CITATIONS
464	Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?. <i>Cancers</i> , 2021, 13, 5756.	1.7	11
465	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations. <i>Frontiers in Pharmacology</i> , 2021, 12, 743073.	1.6	10
466	Bevacizumab and Sinus Venous Thrombosis: A Literature Review. <i>Cureus</i> , 2021, 13, e19471.	0.2	1
467	Anti-Angiogenesis Maintenance Therapy in Newly Diagnosed and Relapsed Ovarian Cancer: A Meta-analysis of Phase III Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 726278.	1.6	2
468	The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers. <i>Cancers</i> , 2021, 13, 5874.	1.7	61
469	Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 5899.	1.7	9
470	Adjuvant taxane plus platinum chemotherapy for stage I ovarian clear cell carcinoma with complete surgical staging: are more than three cycles necessary?. <i>International Journal of Clinical Oncology</i> , 2022, 27, 609-618.	1.0	2
471	Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 1647-1654.	0.8	1
472	Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage IIâ€“IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. <i>Current Oncology</i> , 2022, 29, 231-242.	0.9	3
473	Inhibition of PKM2 Enhances Sensitivity of Olaparib to Ovarian Cancer Cells and Induces DNA Damage. <i>International Journal of Biological Sciences</i> , 2022, 18, 1555-1568.	2.6	16
474	Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. <i>Gynecologic Oncology</i> , 2022, 164, 254-264.	0.6	51
475	Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 836984.	2.0	22
476	Randomised phase II trial of weekly ixabepilone±â€±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. <i>British Journal of Cancer</i> , 2022, 126, 1695-1703.	2.9	5
477	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. <i>BMC Medicine</i> , 2022, 20, 59.	2.3	3
478	Low-Grade Serous Carcinoma of the Ovary: The Current Status. <i>Diagnostics</i> , 2022, 12, 458.	1.3	12
479	Erkrankungen der Adnexe. , 2021, , 461-513.		0
480	The Use of Targeted Agents in the Treatment of Gynecologic Cancers. <i>Current Treatment Options in Oncology</i> , 2022, 23, 15-28.	1.3	3
481	Low-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study. <i>Journal of Cancer Research and Therapeutics</i> , 2022, .	0.3	0

#	ARTICLE	IF	CITATIONS
482	Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers. <i>Cancers</i> , 2022, 14, 1122.	1.7	5
485	Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer. <i>The Cochrane Library</i> , 2022, 2022, CD012007.	1.5	5
486	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives. <i>Cancers</i> , 2022, 14, 1098.	1.7	8
487	CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 798680.	1.3	10
488	Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin. <i>Frontiers in Medicine</i> , 2022, 9, 807377.	1.2	2
489	Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research. <i>Frontiers in Oncology</i> , 2022, 12, 837233.	1.3	2
490	A Weakly Supervised Deep Learning Method for Guiding Ovarian Cancer Treatment and Identifying an Effective Biomarker. <i>Cancers</i> , 2022, 14, 1651.	1.7	18
491	Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1285.	1.7	3
492	A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer. <i>Scientific Reports</i> , 2022, 12, 3803.	1.6	7
493	Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers. <i>Biomarkers in Medicine</i> , 2022, 16, 349-369.	0.6	4
494	Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100953.	0.3	1
495	Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF- β 1/thrombospondin-1 axis. <i>Matrix Biology</i> , 2022, 109, 70-90.	1.5	19
496	Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 6231.	1.7	13
497	Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 4.	1.7	10
498	Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). <i>Current Oncology</i> , 2021, 28, 5266-5277.	0.9	1
499	Traitement mÃ©dical de premiÃ¨re ligne du cancer Ã©pithÃ©lial de lâ€™ovaire de haut grade. <i>Bulletin Du Cancer</i> , 2021, 108, S5-S12.	0.6	3
501	Appropriate Selection of PARP Inhibitors in Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 887-903.	1.3	17
502	Complications after advanced ovarian cancer surgeryâ€™s population-based cohort study. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2022, , .	1.3	3

#	ARTICLE	IF	CITATIONS
506	Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 415-423.	0.9	8
507	Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort. <i>Medicina (Lithuania)</i> , 2022, 58, 607.	0.8	0
508	Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 142.	7.1	62
509	The roles and limitations of bevacizumab in the treatment of ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1120-1126.	1.0	14
510	Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?. <i>Cancers</i> , 2022, 14, 2353.	1.7	0
511	Shifting the Soil: Metformin Treatment Decreases the Protumorigenic Tumor Microenvironment in Epithelial Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2298.	1.7	4
512	Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. <i>BMC Cancer</i> , 2022, 22, 508.	1.1	4
513	The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	6
514	Maelstrom promotes tumor metastasis through regulation of FGFR4 and epithelial-mesenchymal transition in epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2022, 15, 55.	1.3	1
515	Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2021, .	0.4	1
517	State of the science: Contemporary front-line treatment of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 166, 18-24.	0.6	6
518	The Value of Magnetic Resonance Diffusion-Weighted Imaging and Dynamic Contrast Enhancement in the Diagnosis and Prognosis of Treatment Response in Patients with Epithelial Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2464.	1.7	5
519	Rotational intraperitoneal pressurized aerosol chemotherapy with paclitaxel and cisplatin: pharmacokinetics, tissue concentrations, and toxicities in a pig model. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	2
520	Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
521	Is there a "low-risk" patient population in advanced epithelial ovarian cancer?: a critical analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 728-734.	0.7	3
522	Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. <i>British Journal of Cancer</i> , 2022, 127, 1034-1042.	2.9	14
523	The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6911.	1.8	13
524	VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients. <i>PLoS ONE</i> , 2022, 17, e0269680.	1.1	1

#	ARTICLE	IF	CITATIONS
525	Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tuning as Multi-Target Therapeutics against Ovarian Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6857.	1.8	8
526	Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (<sc>RESPONSE</sc> trial). <i>Cancer</i> , 2022, 128, 3080-3089.	2.0	7
527	Prolonged Survival and Restored Useful Life by Early Induction of Intrathecal Chemotherapy in a Patient with Leptomeningeal Carcinomatosis from Ovarian Cancer. <i>Brain Sciences</i> , 2022, 12, 748.	1.1	0
528	A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. <i>Current Oncology</i> , 2022, 29, 4354-4369.	0.9	1
529	Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program. <i>Meditinskiy Sovet</i> , 2022, , 77-83.	0.1	0
530	Weakly supervised deep learning for prediction of treatment effectiveness on ovarian cancer from histopathology images. <i>Computerized Medical Imaging and Graphics</i> , 2022, 99, 102093.	3.5	17
531	The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3318.	1.7	1
532	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 919-930.	5.1	11
533	Maintenance therapy for newly diagnosed epithelial ovarian cancer – a review. <i>Journal of Ovarian Research</i> , 2022, 15, .	1.3	11
534	Listening to the Patient Voice Adds Value to Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1323-1332.	3.0	10
535	CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 107-116.	0.8	9
536	Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database. <i>Cancers</i> , 2022, 14, 4040.	1.7	0
537	Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
538	Patterns of First-Line Systemic Therapy Delivery and Outcomes in Advanced Epithelial Ovarian Cancer in Ontario. <i>Current Oncology</i> , 2022, 29, 5988-6009.	0.9	0
539	CDCA3 exhibits a role in promoting the progression of ovarian cancer. <i>Tissue and Cell</i> , 2022, 79, 101903.	1.0	3
540	Ovarian clear cell carcinoma. , 2023, , 55-76.		0
541	Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial. <i>ESMO Open</i> , 2022, 7, 100585.	2.0	13
542	Extracts of the Medicinal Plants <i>Pao Pereira</i> and <i>Rauwolfia vomitoria</i> Inhibit Ovarian Cancer Stem Cells <i>In Vitro</i> . <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211230.	0.8	1

#	ARTICLE	IF	CITATIONS
543	Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer. <i>PharmacoEconomics - Open</i> , 2022, 6, 811-822.	0.9	4
544	Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab. <i>Diagnostics</i> , 2022, 12, 2118.	1.3	2
546	Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer. <i>Future Oncology</i> , 0, , 00-00.	1.1	0
547	Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1. <i>Seminars in Cancer Biology</i> , 2022, 86, 126-135.	4.3	10
548	Personalized Treatment in Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 1-19.	0.0	0
549	Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by an Expert Group from Middle East and North Africa Region. <i>Current Women's Health Reviews</i> , 2022, 19, .	0.1	0
550	Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3965-3974.	0.8	21
552	Targeting the tumor stroma for cancer therapy. <i>Molecular Cancer</i> , 2022, 21, .	7.9	71
553	Body composition as a predictor of chemotherapy-related toxicity in ovarian cancer patients: A systematic review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
554	Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. <i>European Journal of Cancer</i> , 2023, 178, 162-170.	1.3	1
555	Epithelial ovarian cancer. , 2023, , 250-281.e8.		0
556	Targeted therapy and molecular genetics. , 2023, , 464-488.e11.		0
557	A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	0
559	Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer â€“ Navigating maintenance therapy for homologous recombinant proficient ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2022, 44, 101103.	0.3	0
560	Low grade serous ovarian cancer â€“ A rare disease with increasing therapeutic options. <i>Cancer Treatment Reviews</i> , 2023, 112, 102497.	3.4	4
561	Update on new treatments for rare ovarian tumours. <i>Current Opinion in Obstetrics and Gynecology</i> , 2023, 35, 27-33.	0.9	2
562	Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatmentâ€free survival analysis of the <scp>AICE</scp> trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 32-39.	1.1	1
563	Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
564	Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial. <i>European Journal of Cancer</i> , 2023, 181, 42-52.	1.3	5
566	Impact of consolidation chemotherapy after delayed complete surgery in advanced epithelial ovarian cancer: a propensity score analysis. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003920.	1.2	0
567	Towards Personalized Management of Ovarian Cancer. <i>Cancer Management and Research</i> , 0, Volume 14, 3469-3483.	0.9	4
568	Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 543-548.	1.2	1
569	Molecular Profiling of Gynaecological Cancer and Breast Cancer. , 2022, , 9-24.		0
570	Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary. <i>JCO Oncology Practice</i> , 0, , .	1.4	0
571	Diagnostic and Therapeutic Pathway of Advanced Ovarian Cancer with Peritoneal Metastases. <i>Cancers</i> , 2023, 15, 407.	1.7	2
572	Disparity in the era of personalized medicine for epithelial ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211480.	1.4	1
573	Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis. <i>American Journal of Therapeutics</i> , 2023, 30, e36-e55.	0.5	4
574	Tumor-Bowel Fistula as a Rare Form of Recurrent Ovarian Cancer—Imaging and Treatment: Preliminary Report. <i>Current Oncology</i> , 2023, 30, 506-517.	0.9	1
575	High tyrosine threonine kinase expression predicts a poor prognosis: a potential therapeutic target for endometrial carcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 1352-1352.	0.7	1
576	Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
577	Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer. <i>Cancers</i> , 2023, 15, 1067.	1.7	5
578	An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 170, 290-299.	0.6	7
579	Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, , .	0.9	1
580	Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	0
581	Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188888.	3.3	3
583	Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study. <i>Journal of the National Cancer Institute</i> , 2023, 115, 570-577.	3.0	1

#	ARTICLE	IF	CITATIONS
584	Epithelial Ovarian Cancer. , 2022, , 291-323.		1
585	Comprehensive Analysis of the Expression and Clinical Significance of a Ferroptosis-Related Genome in Ovarian Serous Cystadenocarcinoma: A Study Based on TCGA Data. <i>Oncologie</i> , 2022, 24, 835-863.	0.2	5
586	Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial. <i>Gynecologic Oncology</i> , 2023, 170, 186-194.	0.6	3
587	Deep Learning Provides a New Magnetic Resonance Imaging-Based Prognostic Biomarker for Recurrence Prediction in High-Grade Serous Ovarian Cancer. <i>Diagnostics</i> , 2023, 13, 748.	1.3	2
588	Impact of complete surgical staging on survival of patients with early-stage (FIGO I or II) ovarian cancer: Data from the Cote d'Or Registry of Gynecological Cancers from 1998 to 2015. <i>Bulletin Du Cancer</i> , 2023, 110, 352-359.	0.6	1
590	Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2023, 13, 1040.	1.3	0
591	Ovarian Cancer—Insights into Platinum Resistance and Overcoming It. <i>Medicina (Lithuania)</i> , 2023, 59, 544.	0.8	5
592	Prediction of Surgical Outcome in Advanced Ovarian Cancer by Imaging and Laparoscopy: A Narrative Review. <i>Cancers</i> , 2023, 15, 1904.	1.7	5
594	Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer. <i>Bulletin Du Cancer</i> , 2024, 111, 277-284.	0.6	2
596	Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. <i>The Cochrane Library</i> , 2023, ,	1.5	1
623	Molecular Characterization of Single Circulating Tumor Cells in Breast and Ovarian Cancer. <i>Current Cancer Research</i> , 2023, , 327-358.	0.2	0
624	Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options. <i>Drugs</i> , 2023, 83, 1365-1385.	4.9	0
630	Epithelial Ovarian Cancer: High Grade Serous. , 2023, , 15-30.		0
637	<i>Gynecologic Cancer</i> . , 2023, , 1-48.		0
654	Advances in the Medical Management of Ovarian Cancer. , 2023, , 345-396.		0